Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio
Buying Allergan's US dermatology portfolio will expand the Spanish group's platform in the world's largest dermatology market.
You may also be interested in...
CEO Peter Guenter’s focus on first- and best-in-class looks like the right strategy as Spanish pharma builds critical mass in dermatology.
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.
In the third quarter, generics of dry eye drug Restasis did not emerge as expected and Botox enjoyed double digit sales for therapeutic indications in the US, despite the entry of new competition in migraine treatment.